Download Free Non Coding Rna In Immunotherapies And Immune Regulation Book in PDF and EPUB Free Download. You can read online Non Coding Rna In Immunotherapies And Immune Regulation and write the review.

This volume presents techniques needed for the study of long non-coding RNAs (lncRNAs) in cancer from their identification to functional characterization. Chapters guide readers through identification of lncRNA expression signatures in cancer tissue or liquid biopsies by RNAseq, single Cell RNAseq, Phospho RNAseq or Nanopore Sequencing techniques; validation of lncRNA signatures by Real time PCR, digital PCR or in situ hybridization; and functional analysis by siRNA or CRISPR based methods for lncRNA silencing or overexpression. Lipid based nanoparticles for delivery of siRNAs in vivo, lncRNA-protein interactions, viral lncRNAs and circRNAs are also treated in this volume. Written in the format of the highly successful Methods in Molecular Biology series, each chapter includes an introduction to the topic, lists necessary materials and reagents, includes tips on troubleshooting and known pitfalls, and step-by-step, readily reproducible protocols. Authoritative and practical, Long Non-Coding RNAs in Cancer aims to provide a collection of laboratory protocols, bioinformatic pipelines, and review chapters to further research in this vital field.
During the past few decades, immunotherapy has become an established pillar of cancer treatment improving the survival of numerous patients with diverse solid and hematologic tumors. The leading causes behind the success are the discovery of immune checkpoint inhibitors (ICIs) and the development of chimeric antigen receptor (CAR) T/M/NK cells. As for ICIs, malignancies take advantage of the inhibitory programmed cell death protein 1/programmed cell death protein ligand 1 (PD-1/PD-L1) or cytotoxic T-lymphocyte-associated protein (CTLA-4) pathways to evade the immune system, and disruption of the axis by immune checkpoint inhibitors can achieve durable disease remissions, which has been proved by basic researches and (pre-) clinical studies among lung cancer, melanoma, renal cell cancer, head, and neck squamous cell carcinoma, urothelial cancer, and Hodgkin’s disease. However, the 5-year survival rate of patients treated with ICIs varies with each individual and also relies on tumor specific pathological or molecular subtypes. Besides, the efficacy of ICIs is still limited in terms of drug resistance and fewer potential responders. Thus, there is a big challenge to identify and develop more novel reliable ICIs, as well as sensibilize existing ICIs for patients with drug resistance or even for non-responders.
Immunotherapeutics, Volume 129 in the Advances in Protein Chemistry and Structural Biology series highlights new advances in the field, with this new volume presenting interesting chapters on a variety of topics, including Vaccines for the prophylaxis and treatment of HPV, Lung-targeted RNA-based therapeutics, Clostridium difficile: Current overview and future perspectives, Antivenoms for treatment of snake bites, Natural killer cell-based strategies for immunotherapy of cancer, Immunological insights of selectins in human disease mechanism, Current update, challenges, and future aspects of immunotherapeutics in non-small cell lung cancer, In silico interaction analysis of NEMO binding domain peptide on the NFkB protein, and much more. - Provides the authority and expertise of leading contributors from an international board of authors - Presents the latest release in the Advances in Protein Chemistry and Structural Biology series - Updated release includes the latest information on Immunotherapeutics